Serodus ASA (Oslo Axess: SER) Torben Skarsfeldt (Project Director) has today purchased 15 000 shares at an average price of NOK 2,30 per share through his whole owned company Pharma Guidance Aps. After registration of these shares Dr. Skarsfeldt holds 15 000 shares and 50 000 warrants.
Serodus ASA (Oslo Axess: SER) Eva Steiness (CEO) has today purchased 24 900 shares at an average price of NOK 2,30 per share through here whole owned company newpharma Aps. After registration of these shares Eva Steiness has 886 041 shares and 100 000 warrants.
Serodus ASA (Oslo Axess: SER) Tore Kvam (CFO) has today purchased 20 000 shares at an average price of NOK 2,40 per share through his wholly owned company Itza AS. After registration of these shares Tore Kvam owns 20 000 shares through his wholly owned company Itza AS.
Serodus has been informed that the IP Australia Office has decided to grant the patent "Substituted 1,3-Dioxanes useful as PPAR Modulators". The patent is one of four families related to SER150.
Serodus ASA (Oslo Axess: SER) Eva Steiness (CEO) has today purchased 20 000 shares at an average price of NOK 3,24 per share. After registration of these shares Dr. Steiness has 861 141 shares and 100 000 warrants. For more information contact: Tore Kvam CFO, Serodus ASA Mobile: +47 959 34 199 e-mail: firstname.lastname@example.org
Oslo, October 27, 2014: Serodus ASA (Oslo Axess: SER), the following transactions has today been exercised:
Oslo 20 October 2014: Serodus ASA (Oslo Axess: SER), has updated the financial calendar. The presentation of Q3 Results 2014 will be held 23. October 2014, a change from previously communicated.
Oslo, 15 September 2014: With reference to the previously announced Capital Markets Day the lectures and presentations are available on www.serodus.com.
Serodus announces positive results on the clinical study of SER100 in patients with systolic hypertension
Serodus ASA (Oslo Axess: SER), today announced that the outcome of the SER100 clinical study in patients with systolic hypertension was successful.
Oslo, September 03, 2013: Serodus ASA (Oslo Axess: SER), the following transactions has today been exercised:
Serodus has been informed that the U.S. Patent and Trademark Office has issued a notice of allowance for the patent application "Prodrugs of Substituted 1,3-Dioxanes and their Uses".
Serodus ASA (Oslo Axess: SER), a Norwegian cardiovascular biopharmaceutical company, successfully completed the enrollment of patients into the Phase IIa - safety study for SER100. SER100 is being developed for the treatment of Isolated Systolic Hypertension, a common condition associated with an increased risk of stroke and heart attack.
Serodus ASA (SER) has appointed Tore Kvam as new Chief Financial Officer (CFO). He will head Serodus accounting and finance department including investor relations.
The annual ahareholders meeting in Serodus ASA will take place Thursday 24 April at 1700 in Forskningsparken, Gaustadalleen 21 Oslo.
The CEO of Serodus, Eva Steiness, will present the company at the AngloNordic Biotech Conference in London on 10 April 2014.
The Subsequent Offering was completed on 12 February 2014 at 16:30 hours CET in Serodus ASA and was significantly oversubscribed. As a result of the Subsequent Offering, Serodus will issue 3,500,000 Offer Shares at NOK 3.00 per share raising gross proceeds of NOK 10,500,000.
In connection with the Private Placement completed in Serodus ASA on the 6 December 2013, raising a total of NOK 30 million, Serodus ASA is currently completing a Subsequent Offering to shareholders in Serodus as of 5 December 2013, as recorded in the VPS on 10 December 2013, who did not participate in the Private Placement and who are not resident in a jurisdiction where such offering would be unlawful, or would (in jurisdictions other than Norway) require any prospectus filing, registration or similar action.
Serodus has been granted 5.9 MNOK from the Norwegian Research Council's BIA-program. The project focuses on testing of SER130 in experimental pharmacological models, other pre-clinical testing and in patients with acute heart attack. SER130 is expected to reduce the size of tissue damage after the attack. The pharmacological testing will be in collaboration with the Univiersitaetsklinikum Essen in Germany. The clinical effect of SER130 on tissue damage after Acute Heart Attack will be studied in collaboration with the Department of Cardiology and Internal Medicine at Oslo University Hospital. The total study period is 2014 - 2017. CEO Eva Steiness, Serodus, expresses her gratitude of the scientific validation of our SER130 program and look forward to initiate the studies.
The protocol from the extraordinary general meeting and the presentation given by the CEO can be downloaded from below.
Norne Securities has issued a new analyst report for Serodus. The report can be downloaded from the Investor Relations pages.
Serodus ASA - Board decision related to subsequent offering.